top of page
Latest News
March 2026
February 2026
January 2026
Validation of Physics-Aware AI in TCR Engineering
We have successfully validated our proprietary platform through a series of high-fidelity simulations, demonstrating unprecedented accuracy in predicting protein-protein interactions for next-generation TCR therapeutics.
Securing Strategic Institutional Investment
Escalante Therapeutics has closed a significant round of institutional funding to accelerate the development of our KRAS-targeted pipeline and expand our Austin research facility.
AI-Driven Drug Discovery Award 2026
Our team has been honored with the prestigious 'Innovation in Computational Biology' award for our groundbreaking integration of machine learning into protein engineering workflows.
Research Milestone
Funding Update
Industry Recognition
bottom of page